The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats

Abstract

AbstractBackgroundImatinib is mainly metabolized by CYP3A4 and to a lesser extent by other isoenzymes, withN-desmethyl imatinib being its major equipotent metabolite. Being a CYP3A4 substrate, imatinib co-administration with CYP3A4 modulators would change its pharmacokinetic profile. The cancer chemoprevention potential and anticancer efficacy of many herbal products such as grape seed (GS) and green tea (GT) extracts had led to an increase in their concomitant use with anticancer agents. GS and GT extracts were demonstrated to be potent inhibitors of CYP3A4. The aim of this study is to investigate the effect of standardized GS and/or GT extracts at two different doses on the pharmacokinetics of imatinib and its metabolite,N-desmethyl imatinib, in SD-rats.MethodsStandardized GS and/or GT extracts were administered orally once daily for 21 days, at low (l) and high (h) doses, 50 and 100 mg/kg, respectively, before the administration of a single intragastric dose of imatinib. Plasma samples were collected and analyzed for imatinib andN-desmethyl imatinib concentrations using LC-MS/MS method, then their non-compartmental pharmacokinetic parameters were determined.Resultsh-GS dose significantly decreased imatinib’s Cmaxand the$$ {\mathrm{AUC}}_0^{\infty } $$AUC0∞by 61.1 and 72.2%, respectively. Similar effects onN-desmethyl imatinib’s exposure were observed as well, in addition to a significant increase in its clearance by 3.7-fold.l-GT caused a significant decrease in imatinib’s Cmaxand$$ {\mathrm{AUC}}_0^{\infty } $$AUC0∞by 53.6 and 63.5%, respectively, with more significant effects onN-desmethyl imatinib’s exposure, which exhibited a significant decrease by 79.2 and 81.1%, respectively.h-GT showed similar effects as those ofl-GT on the kinetics of imatinib and its metabolite. However, when these extracts were co-administered at low doses, no significant effects were shown on the pharmacokinetics of imatinib and its metabolite. Nevertheless, increasing the dose caused a significant decrease in CmaxofN-desmethyl imatinib by 71.5%.ConclusionsThese results demonstrated that the pharmacokinetics of imatinib andN-desmethyl imatinib had been significantly affected by GS and/or GT extracts, which could be partially explained by the inhibition of CYP3A-mediated metabolism. However, the involvement of other kinetic pathways such as other isoenzymes, efflux and uptake transporters could be involved and should be characterized.Graphical abstract